Morning Movers Gapping up $ドアダッシュ(DASH.US)$stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential. $ロイバント・サイエンシズ(ROIV.US)$stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study. Gapping down $ニオ(NIO.US)$fell ...
The sale of Roivant Sciences shares by an insider, without any recent insider buying, and a high insider ownership can signal mixed sentiments towards the company's future prospects. It could perpetuate caution among potential investors.
$ロイバント・サイエンシズ(ROIV.US)$extremely undervalued, by at least 60%? Roivant stock was already priced at ~ $7 with a market cap of $5 Billion when it licensed RVT-3101 from Pfizer for $45 million back in Dec, 2022. Now Roivant just pocketed $5 billion from selling it to Roche, so its stock price shall at least raise to $14 to justify the huge gain only from the Roche deal by simple math, that's probably also why its average analyst price target is about $16.
MACRO Bill Ackman Cashes Out Bet Against Treasury Bonds as Yields Hit 16-year Highs One of Wall Street's most prominent bond bears has decided to walk away with his gains, declaring that Treasury yields are likely poised for a turnaround following an ascent that rattled global markets. Pershing Square's Bill Ackman said Monday that he has closed his bet against 30-year Treasury bonds, saying in a ser...
Analyst David Risinger from Leerink Partners sees the deal as a 'transformative transaction' for Roivant and looks forward to hearing how the company plans to reinvest the cash.
$ロイバント・サイエンシズ(ROIV.US)$The Swiss pharmaceutical giant said Monday that it will pay $7.1 billion upfront and make a near-term milestone payment of $150 million to gain rights in the US and Japan to develop and market the drug known as RVT-3101.
1 | Below is a look at the top insider trades with the biggest value in the past week. One of$イムノバント(IMVT.US)$'s directors and more than 10% owner,$ロイバント・サイエンシズ(ROIV.US)$, recently undertook a vast buy transaction worth $58 million. IMVT stock has gained over 104% since the start of this year. It is worth mentioning that Immunovant is a subsidiary of Roivant Sci...
ロイバント・サイエンシズに関するコメント
コラムToday's Morning Movers and Top Ratings: DIS, DASH, CVS, GE and More
Gapping up
$ドアダッシュ(DASH.US)$ stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential.
$ロイバント・サイエンシズ(ROIV.US)$ stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study.
Gapping down
$ニオ(NIO.US)$ fell ...
Ph2 readouts in Q1 2024...
$リープ・セラピューティクス(LPTX.US)$ Phase 2
$ヴェラ・セラピューティクス(VERA.US)$ Phase 2b
$4Dモレキュラー・セラピューティクス(FDMT.US)$ Phase 2
$アドベラム・バイオテクノロジーズ(ADVM.US)$ Phase 2
$デナリ・セラピューティクス(DNLI.US)$ Phase 2
$アケロ・セラピューティクス(AKRO.US)$ Phase 2b
$スプルース・バイオサイエンシズ(SPRB.US)$ Phase 2
$ゼンコー(XNCR.US)$ Phase 2
$アルナイラム・ファーマシューティカルズ(ALNY.US)$ Phase 2
$ハーモニー・バイオサイエンシーズ(HRMY.US)$ Phase 2
$アネクソン(ANNX.US)$ Phase 2a
$ロイバント・サイエンシズ(ROIV.US)$...
Upcoming Ph 2 readouts in Q1 2024…
$リジェネックスバイオ(RGNX.US)$ Phase 2
$リープ・セラピューティクス(LPTX.US)$ Phase 2
$4Dモレキュラー・セラピューティクス(FDMT.US)$ Phase 2
$アドベラム・バイオテクノロジーズ(ADVM.US)$ Phase 2
$デナリ・セラピューティクス(DNLI.US)$ Phase 2
$アイポイント・ファーマシューティカルズ(EYPT.US)$ Phase 2
$ゼンコー(XNCR.US)$ Phase 2
$ハーモニー・バイオサイエンシーズ(HRMY.US)$ Phase 2
$アルナイラム・ファーマシューティカルズ(ALNY.US)$ Phase 2
$ディスク・メディシン(IRON.US)$ Phase 2
$アテア・ファーマシューティカルズ(AVIR.US)$ Phase 2
$アラコス(ALLK.US)$ Phase 2...
コラムWall Street Today | Bill Ackman Cashes Out Bet Against Treasury Bonds as Yields Hit 16-year Highs
Bill Ackman Cashes Out Bet Against Treasury Bonds as Yields Hit 16-year Highs
One of Wall Street's most prominent bond bears has decided to walk away with his gains, declaring that Treasury yields are likely poised for a turnaround following an ascent that rattled global markets.
Pershing Square's Bill Ackman said Monday that he has closed his bet against 30-year Treasury bonds, saying in a ser...
Loading this
News
コラムWeekly Insider Money Tracking: IMVT director undertook a $58 million buy, and AAPL executives sold over $64 million in stocks.
One of $イムノバント(IMVT.US)$'s directors and more than 10% owner, $ロイバント・サイエンシズ(ROIV.US)$, recently undertook a vast buy transaction worth $58 million. IMVT stock has gained over 104% since the start of this year. It is worth mentioning that Immunovant is a subsidiary of Roivant Sci...
まだコメントはありません